Morgan Stanley Atai Life Sciences N.V. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Morgan Stanley holds 3,494,292 shares of ATAI stock, worth $18.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,494,292

Previous 3,293,535 6.1%

Holding current value

$18.3 Million

Previous $4.48 Million 70.84%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$1.21 - $2.49 $242,915 - $499,884	200,757 Added 6.1%	3,494,292 $7.65 Million
Q1 2025 May 15, 2025	SELL	$1.33 - $2.55 $49,216 - $94,362	-37,005 Reduced 1.11%	3,293,535 $4.48 Million
Q4 2024 Feb 14, 2025	BUY	$1.06 - $1.78 $309,916 - $520,425	292,374 Added 9.62%	3,330,540 $4.43 Million
Q3 2024 May 14, 2025	BUY	$1.16 - $1.64 $370,415 - $523,691	319,324 Added 11.74%	3,038,166 $3.52 Million
Q3 2024 Nov 14, 2024	BUY	$1.16 - $1.64 $370,415 - $523,691	319,324 Added 11.74%	3,038,166 $3.52 Million
Q2 2024 May 14, 2025	SELL	$1.27 - $2.6 $776,856 - $1.59 Million	-611,698 Reduced 18.37%	2,718,842 $3.62 Million
Q2 2024 Oct 17, 2024	BUY	$1.27 - $2.6 $64,641 - $132,337	50,899 Added 1.91%	2,718,842 $3.62 Million
Q2 2024 Aug 14, 2024	BUY	$1.27 - $2.6 $64,641 - $132,337	50,899 Added 1.91%	2,718,842 $3.62 Million
Q1 2024 Oct 17, 2024	SELL	$1.5 - $2.19 $76,348 - $111,468	-50,899 Reduced 1.87%	2,667,943 $5.26 Million
Q1 2024 Aug 16, 2024	SELL	$1.5 - $2.19 $717,957 - $1.05 Million	-478,638 Reduced 15.21%	2,667,943 $5.26 Million
Q1 2024 May 15, 2024	SELL	$1.5 - $2.19 $717,957 - $1.05 Million	-478,638 Reduced 15.21%	2,667,943 $5.26 Million
Q4 2023 Aug 16, 2024	BUY	$1.04 - $1.55 $444,848 - $662,995	427,739 Added 15.73%	3,146,581 $4.44 Million
Q4 2023 Feb 13, 2024	BUY	$1.04 - $1.55 $626,794 - $934,164	602,687 Added 23.69%	3,146,581 $4.44 Million
Q3 2023 Nov 15, 2023	BUY	$1.27 - $2.28 $545,410 - $979,161	429,457 Added 20.31%	2,543,894 $3.28 Million
Q2 2023 Aug 14, 2023	SELL	$1.44 - $2.19 $319,475 - $485,869	-221,858 Reduced 9.5%	2,114,437 $3.64 Million
Q1 2023 May 15, 2023	SELL	$1.17 - $2.7 $92,125 - $212,598	-78,740 Reduced 3.26%	2,336,295 $4.23 Million
Q4 2022 Feb 14, 2023	BUY	$2.38 - $3.55 $172,790 - $257,733	72,601 Added 3.1%	2,415,035 $6.42 Million
Q3 2022 Nov 14, 2022	BUY	$3.14 - $4.87 $594,609 - $922,212	189,366 Added 8.8%	2,342,434 $7.75 Million
Q2 2022 Oct 27, 2022	BUY	$3.03 - $5.32 $1.09 Million - $1.91 Million	358,097 Added 19.95%	2,153,068 $7.84 Million
Q2 2022 Aug 15, 2022	BUY	$3.03 - $5.32 $1.09 Million - $1.91 Million	358,097 Added 19.95%	2,153,068 $7.84 Million
Q1 2022 Oct 27, 2022	SELL	$4.66 - $7.66 $1.67 Million - $2.74 Million	-358,097 Reduced 16.63%	1,794,971 $9.14 Million
Q1 2022 May 13, 2022	BUY	$4.66 - $7.66 $106,648 - $175,306	22,886 Added 1.29%	1,794,971 $9.14 Million
Q4 2021 Feb 14, 2022	BUY	$6.82 - $17.8 $5.38 Million - $14 Million	789,225 Added 80.3%	1,772,085 $13.5 Million
Q3 2021 Nov 15, 2021	BUY	$13.62 - $19.48 $13.4 Million - $19.1 Million	982,860 New	982,860 $14.5 Million

Others Institutions Holding ATAI

# of Institutions

111

Shares Held

31.3M

Call Options Held

494K

Put Options Held

315K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $868M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account